Hyperphosphatemia - Epidemiology Forecast to 2034

Published Date : 2025
Pages : 90
Region : United States, Japan, China, EU4 & UK

Share:

Hyperphosphatemia Epidemiology

Hyperphosphatemia Insights and Trends

  • Hyperphosphatemia is highly prevalent among patients with advanced CKD and ESRD, with risk increasing progressively as renal function declines due to impaired phosphate excretion.
  • According to the NIDDK, CKD prevalence in the US increased from approximately 12% to 14% between 1988–1994 and 1999–2004 and has remained relatively stable thereafter; notably, nearly 90% of CKD patients remain unaware of their condition, contributing to delayed diagnosis and phosphate imbalance progression.
  • The prevalence of ESRD has increased substantially over recent decades, with nearly 71% of ESRD patients receiving dialysis therapy, representing a major at-risk population for hyperphosphatemia and associated cardiovascular complications. 

Hyperphosphatemia Epidemiology Forecast in the 7MM

  • 2025 Diagnosed Prevalent Cases of Hyperphosphatemia: ~ XX
  • 2036 Projected Diagnosed Prevalent Cases of Hyperphosphatemia: ~ XX
  • Hyperphosphatemia Growth Rate (2026–2036): ~XX CAGR

DelveInsight's ‘Hyperphosphatemia Epidemiology Forecast - 2036’ report delivers an in-depth understanding of the Hyperphosphatemia, historical and forecasted epidemiology, in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Study Period

2022–2036

Historical Year

2022–2025

Forecast Period

2026–2036

Base Year

2026

Geographies Covered

  • North America : The US;

  • Europe: Germany, France, Italy, Spain and the UK;

  • Asia-Pacific: Japan

Hyperphosphatemia Epidemiology CAGR

(Forecast period)

~XX% (2026–2036)

Hyperphosphatemia Epidemiology Segmentation Analysis

Patient Burden Assessment

  • Total Prevalent Cases of Chronic Kidney Disease (CKD) 

  • Total Diagnosed Prevalent Cases of CKD 

  • Stage-specific Distribution of CKD

  • Total Prevalent Cases of End-Stage Renal Disease (ESRD)

  • Number of ESRD patients undergoing Dialysis

  • Total Prevalent Cases of Hyperphosphatemia

Hyperphosphatemia Understanding and Diagnosis Algorithm

Hyperphosphatemia Overview and Diagnosis

Hyperphosphatemia is a metabolic disorder characterized by elevated serum phosphate levels, most commonly occurring in patients with advanced chronic kidney disease (CKD) and end-stage renal disease (ESRD) due to impaired renal phosphate excretion. The condition is strongly associated with CKD-mineral and bone disorder (CKD-MBD), secondary hyperparathyroidism, vascular calcification, and increased cardiovascular risk. Persistent hyperphosphatemia contributes significantly to morbidity and mortality in dialysis patients. Current management includes dietary phosphate restriction, dialysis optimization, and phosphate binders; however, long-term phosphate control remains challenging because of high pill burden and tolerability issues. The growing CKD and dialysis population continues to increase the clinical and economic burden of hyperphosphatemia.

Further details are provided in the report.

Hyperphosphatemia Diagnosis

Hyperphosphatemia is diagnosed primarily through serum phosphate testing, with elevated phosphate levels indicating impaired phosphate regulation, most commonly in patients with advanced CKD and ESRD. Diagnosis is supported by evaluation of kidney function, serum calcium, parathyroid hormone (PTH), and vitamin D levels to assess associated CKD-mineral and bone disorder (CKD-MBD). Routine phosphate monitoring is recommended in dialysis and advanced CKD patients due to the strong association of persistent hyperphosphatemia with vascular calcification, cardiovascular complications, and increased mortality risk.

Further details are provided in the report.

Hyperphosphatemia Epidemiology

Key Findings from Hyperphosphatemia Epidemiological Analysis and Forecast 

  • According to DelveInsight, in 2025, in the United States, the prevalent cases of CKD were found to be highest in the age group 65 and above with approximately 1,961,000 cases and followed by age group 45–64 with approximately 1,056,000 cases.
  • There are five stages of CKD defined as Stage 1–5. As per the CDC estimates, the prevalence of ESRD doubled between 1990 and 2016. Secondary findings in 2016 suggested a point prevalence of 2,206 per million population for the ESRD treated pool; the prevalence of dialysis treatment was 1,553 per million, whereas the prevalence of functioning kidney transplant was 653 per million. Furthermore, nearly 71% of patients are on dialysis, and 29% live with a kidney transplant.
  • In a large community-based cohort study from the QICKD trial, hyperphosphatemia (>1.50 mmol/L) was observed in 4.3% of patients with CKD stages I–II and 22.4% of patients with CKD stages III–V who experienced cardiovascular events, highlighting the increasing burden of hyperphosphatemia with worsening CKD severity.
  • Hyperphosphatemia is observed in approximately 1.4% of patients with CKD stages I–II, while its prevalence increases to around 2.3% in patients with CKD stages III–IV.
  • Elevated serum phosphate levels are associated with increased risks of vascular calcification, cardiovascular disease, all-cause mortality, and hospitalization, particularly among dialysis-dependent CKD populations.
  • Hyperphosphatemia is a common laboratory abnormality encountered by nephrologists. In patients with ESRD, the prevalence of hyperphosphatemia varies from 50 to 74%. Among children with oncologic disorders who received liposomal amphotericin, nearly 45% of children developed hyperphosphatemia.

Scope of the Report

  • The report covers a segment of a descriptive overview of hyperphosphatemia, explaining their causes, signs and symptoms, and pathogenesis.
  • Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression. 

Report Insights

Hyperphosphatemia Patient Population Forecast

Report Key Strengths

  • Epidemiology‑based (Epi‑based) Bottom‑up Forecasting
  • 11-year Forecast 
  • Patient Burden Trends (by geography)

FAQs

  • What are the disease risks, burdens, and unmet needs of hyperphosphatemia? What will be the growth opportunities across the 7MM concerning the patient population with hyperphosphatemia?
  • What is the historical and forecasted Hyperphosphatemia patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

  • Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
  • To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
  • Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Tags:

    Related Reports

    report image delveinsight

    Hyperphosphatemia- Market Insight, Epidemiology and Market Forecast -2030

    report image delveinsight

    Hyperphosphatemia - Pipeline Insight, 2026

    report image delveinsight

    Hyperphosphatemia - Epidemiology Forecast - 2034

    report image delveinsight

    Hyperphosphatemia - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2026

    License Type

    Offer

    Request Sample

    View Pricing

    Customize Reports As Per Your Needs

    Don't see what you're looking for? Get a report tailored to your specific requirements. Customize your report now!

    Have a Question?

    We are happy to assist you.

    Support Person
    DelveInsight
    DelveInsight
    SUBSCRIPTION
    Platform

    Register for free trial today and gain instant access to 7000+ market
    research reports

    Latest Press Release